- Associated Press•11 hours ago
On a per-share basis, the San Diego-based company said it had a loss of 24 cents. The developer of cell therapies posted revenue of $1.5 million in the period. For the year, the company reported that its ...
- American City Business Journals•2 months ago
Azaya Therapeutics Inc., a San Antonio-based cancer drug developer, has agreed to sell its assets to Cytori Therapeutics Inc., a specialty pharmaceutical company based in San Diego, in a deal potentially worth $170 million. Under the terms of the agreement, at closing, Cytori (CYTX) will issue $2 million of its common stock and be responsible for about $2 million of Azaya’s trade payables. Azaya Chairman John Kerr said talks with Cytori began last August.
- MarketWatch•2 months ago
Cytori Therapeutics Inc. stock surged 7.9% to $1.78 per share in morning trade Thursday after the company said it had agreed to purchase assets from privately-held Azaya Therapeutics. Under the terms of ...
CYTXW : Summary for Cytori Therapeutics Inc - Yahoo Finance
Cytori Therapeutics Inc (CYTXW)
NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
|Bid||0.01 x 100|
|Ask||9.94 x 100|
|Day's Range||0.63 - 0.69|
|52 Week Range||0.63 - 0.69|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|